Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: A retrospective cost-effectiveness analysis

Journal of Medical Economics

Volumn 15, Issue 2, 2012, Pages 293-304

  Naci, Huseyin ^a   De Lissovoy, Gregory ^b   Hollenbeak, Christopher ^c   Custer, Brian ^d   Hofmann, Axel ^e   McClellan, William ^f   Gitlin, Matthew ^g  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

^d BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^e Medical Society for Blood Management   (Austria)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g AMGEN INC   (United States)

Author keywords

Cost effectiveness analysis; Dialysis; Economic evaluation; End stage renal disease; Erythropoietin

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MEDICARE; MORTALITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; STATISTICAL MODEL; SYSTEMATIC REVIEW;

ANEMIA; BLOOD TRANSFUSION; COHORT STUDIES; COST-BENEFIT ANALYSIS; ERYTHROPOIETIN; HEALTH CARE COSTS; HUMANS; INSURANCE COVERAGE; KIDNEY FAILURE, CHRONIC; MARKOV CHAINS; MEDICARE; QUALITY-ADJUSTED LIFE YEARS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84858117044     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.644407     Document Type: Article

References (40)

1. Goodnough LT, Brecher ME, Kanter MH, et al. Transfusion medicine. First of two parts-blood transfusion. N Engl J Med 1999;340:438-47 (Pubitemid 29084776)
2. Mossey RT, Sondheimer J. Listeriosis in patients with long-term hemodialysis and transfusional iron overload. Am J Med 1985;79:397-400 (Pubitemid 15232517)
3. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of endstage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-8 (Pubitemid 17052741)
4. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 1990;300:573-8
5. Churchill DN, Taylor DW, Cook RJ,] et al. Canadian Hemodialysis Morbidity Study. Am J Kidney Dis 1992;19:214-346.
6. Clement FM, Klarenbach S, Tonelli M, et al. An economic evaluation of erythropoiesis-stimulating agents in CKD. Am J Kidney Dis 2010;56:1050-61
7. Tonelli M, Winkelmayer WC, Jindal KK, et al. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int 2003; 64:295-304 (Pubitemid 36714184)
8. USRDS. 2008 Annual Data Report; 2008 Contract No.: Document Number
9. USRDS. 2005 Annual Data Report; 2005 Contract No.: Document Number
10. Fleurence RL, Hollenbeak CS. Rates and probabilities in economic modelling: transformation, translation and appropriate application. Pharmaco Economics 2007;25:3-6 (Pubitemid 46072364)
11. National Institute for Health and Clinical Excellence, CG39 Anaemia management in chronic kidney disease: full guideline, September 2006
12. Tonelli MK, Wiebe N, Shrive F, et al. Erythropoiesis-Stimulating Agents for Anemia of Chronic Kidney Disease: Systematic Review and Economic Evaluation. Ottowa: Canadian Agency for Drugs and Technologies in Health; 2008 Contract No.: Document Number
13. Rao PS, Schaubel DE, Jia X, et al. Survival on dialysis post-kidney transplant failure: results from the Scientific Registry of Transplant Recipients. Am J Kidney Dis 2007;49:294-300 (Pubitemid 46178401)
14. Evans RW, Manninen DL, Garrison Jr LP, et al. The quality of life of patients with end-stage renal disease. N Engl J Med 1985;312:553-9 (Pubitemid 15174151)
15. Finkelstein FO, Story K, Firanek C, et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol 2009;4:33-8
16. Fryback DG, Lawrence WF, Martin PA, et al. Predicting Quality of Well-being scores from the SF-36: results from the Beaver Dam Health Outcomes Study. Med Decis Making 1997;17:1-9 (Pubitemid 27020134)
17. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996;50:235-42 (Pubitemid 26323718)
18. Collins AJ, Li S, St Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001;12:2465-73 (Pubitemid 33021125)
19. Xia H, Ebben J, Ma JZ, et al. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 1999;10:1309-16 (Pubitemid 29246997)
20. Karpinski M, Pochinco D, Dembinski I, et al. Leukocyte reduction of red blood cell transfusions does not decrease allosensitization rates in potential kidney transplant candidates. J Am Soc Nephrol 2004;15:818-24 (Pubitemid 38294813)
21. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989;111:992-1000 (Pubitemid 20034923)
22. Nissenson AR, Korbet S, Faber M, et al. Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol 1995;5:1517-29
23. Remak E, Hutton J, Jones M, et al. Changes in cost-effectiveness over time. The case of epoetin alfa for renal replacement therapy patients in the UK. Eur J Health Econ 2003;4:115-21 (Pubitemid 36841521)
24. Eschbach JW, Adamson JW. Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy. Kidney Int Suppl 1999;69:S35-43 (Pubitemid 29113581)
25. Hakim RM, Stivelman JC, Schulman G, et al. Iron overload and mobilization in long-term hemodialysis patients. Am J Kidney Dis 1987;10:293-9 (Pubitemid 18046504)
26. Schreiber GB, Busch MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334:1685-90 (Pubitemid 26193619)
27. Shander A, Hofmann A, Ozawa S, et al. Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion 2010;50:753-65
28. Lee CP, Chertow GM, Zenios SA. An emperic estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health 2009;12:80-7
29. Shiroiwa T, Sung YK, Fukuda T, et al. International survey on willingness-topay (WTP) for one additional AQLY gained: what is the threshold of cost effectiveness? Health Econ 2010;19:422-37
30. Menzin J, Lines LM, Weiner DE, et al. A review of the costs and cost effectiveness of interventions in chronic kidney disease: implications for policy. Pharmaco Economics 2011;29:839-61
31. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-84 (Pubitemid 44749316)
32. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32
33. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98 (Pubitemid 44749317)
34. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target. Available at: http://www.kidney.org/professionals/KDOQI/guidelines-anemiaUP/ guide1.htm. Accessed on: November 9, 2011
35. Ebben JP, Gilbertson DT, Foley RN, et al. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006;1:1205-10
36. Marsden PA. Treatment of anemia in chronic kidney disease-strategies based on evidence. N Engl J Med 2009;361:2089-90
37. Lee H, Manns B, Taub K, et al. Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis 2002;40:611-22 (Pubitemid 34971291)
38. Cantor SB, Hudson Jr. DV, Lichtiger B, et al. Costs of blood transfusion: a process-flow analysis. J Clin Oncol 1998;16:2364-70 (Pubitemid 28309029)
39. Payne KA, Desrosiers MP, Caro JJ, et al. Clinical and economic burden of infused iron chelation therapy in the United States. Transfusion 2007;47:1820-9 (Pubitemid 47438548)
40. Coyle D, Lee KM, Fergusson DA, et al. Cost effectiveness of epoetin-alpha to augment preoperative autologous blood donation in elective cardiac surgery. Pharmaco Economics 2000;18:161-71 (Pubitemid 30624899)